HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Abstract
Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.
AuthorsMorten Orebo Holmström, Hans Carl Hasselbalch, Mads Hald Andersen
JournalOncoimmunology (Oncoimmunology) 2017 Vol. 6 Issue 11 Pg. e1358334 ISSN: 2162-4011 [Print] United States
PMID29147619 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: